SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-351265"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-351265" > Neoadjuvant Therapy...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005910naa a2200553 4500
001oai:DiVA.org:uu-351265
003SwePub
008180611s2018 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:137735442
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3512652 URI
0247 a https://doi.org/10.1016/j.clcc.2017.09.0022 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1377354422 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Babaei, Masoudu German Canc Res Ctr, Div Clin Epidemiol & Aging Res, INF 581, Heidelberg, Germany.4 aut
2451 0a Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries :b Variations and Outcomes
264 1b Elsevier BV,c 2018
338 a print2 rdacarrier
520 a This study is the largest observational study on neoadjuvant therapy in patients with stage II & III rectal cancer by including high-quality data from large population-based and clinical cancer registries. We observed large variations in administration of neoadjuvant chemo(radio) therapy across European countries. Our results support major survival advantages of patients treated with neoadjuvant radiotherapy. Background: Neoadjuvant therapy improves survival of patients with clinical stage II and III rectal cancer in clinical trials. In this study, we investigated the administration of neoadjuvant radiotherapy (neo-RT) and neoadjuvant chemoradiotherapy (neo-CRT) and its association with survival in resected patients in 2 European countries (The Netherlands and Sweden) and at 3 specialist centers. Materials and Methods: Administration of neoadjuvant treatment (all registries) and overall survival after surgery in The Netherlands and Sweden were assessed. Hazard ratios (HRs) were obtained using Cox regression adjusted for potential confounders. Results: A total of 16,095 rectal cancer patients with clinical stage II and III were eligible for analyses. Large variations in administration of neo-RT and neo-CRT were observed. Elderly patients less often received neo-RT and neo-CRT. Patients with stage III disease received neo-CRT more frequently than neo-RT. Administration of neo-RT versus surgery without neoadjuvant treatment was significantly associated with improved survival in The Netherlands (HR, 0.62; 95% confidence interval [CI], 0.53-0.73) as well as in Sweden (HR, 0.79; 95% CI, 0.69-0.90). Administration of neo-CRT was associated with enhanced survival in The Netherlands (HR, 0.62; 95% CI, 0.50-0.78) but not in Sweden (HR, 0.97; 95% CI, 0.80-1.18). The mortality of patients treated with neo-CRT compared with neo-RT showed inconsistent results in population-based centers. Conclusions: Our results support an association of neo-RT with enhanced survival among stage II and III rectal cancer patients. Comparing neo-CRT with neo-RT, larger variations and inconsistent results with respect to survival were observed across centers.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Long-term outcomes
653 a Neoadjuvant therapy
653 a Rectal cancer
653 a Survival
653 a Variations
7001 a Jansen, Linau German Canc Res Ctr, Div Clin Epidemiol & Aging Res, INF 581, Heidelberg, Germany.4 aut
7001 a Balavarca, Yesildau German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany.;Natl Ctr Tumor Dis, Heidelberg, Germany.4 aut
7001 a Sjovall, Annikau Karolinska Institutet4 aut
7001 a Bos, Amandau Comprehens Canc Org Netherlands, Utrecht, Netherlands.;Erasmus MC Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands.4 aut
7001 a van de Velde, Tonyu Netherlands Canc Inst, Biometr Dept, Amsterdam, Netherlands.4 aut
7001 a Moreau, Michelu Inst Jules Bordet, Datactr, Brussels, Belgium.4 aut
7001 a Liberale, Gabrielu Inst Jules Bordet, Datactr, Brussels, Belgium.4 aut
7001 a Goncalves, Ana Filipau Portuguese Oncol Inst Porto, Porto, Portugal.4 aut
7001 a Bento, Maria Joseu Portuguese Oncol Inst Porto, Porto, Portugal.4 aut
7001 a Ulrich, Cornelia M.u German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany.;Natl Ctr Tumor Dis, Heidelberg, Germany.;German Canc Res Ctr, German Canc Consortium, Heidelberg, Germany.4 aut
7001 a Schrotz-King, Petrau German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany.;Natl Ctr Tumor Dis, Heidelberg, Germany.4 aut
7001 a Lemmens, Valeryu Comprehens Canc Org Netherlands, Utrecht, Netherlands.;Erasmus MC Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands.4 aut
7001 a Glimelius, Bengtu Uppsala universitet,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)bengglim
7001 a Brenner, Hermannu German Canc Res Ctr, Div Clin Epidemiol & Aging Res, INF 581, Heidelberg, Germany.;German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany.;Natl Ctr Tumor Dis, Heidelberg, Germany.;German Canc Res Ctr, German Canc Consortium, Heidelberg, Germany.4 aut
7102 a German Canc Res Ctr, Div Clin Epidemiol & Aging Res, INF 581, Heidelberg, Germany.b German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany.;Natl Ctr Tumor Dis, Heidelberg, Germany.4 org
7730 t Clinical colorectal cancerd : Elsevier BVg 17:1, s. E129-E142q 17:1<E129-E142x 1533-0028x 1938-0674
8564 u https://europepmc.org/articles/pmc6002839?pdf=render
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-351265
8564 8u https://doi.org/10.1016/j.clcc.2017.09.002
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:137735442

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy